Guggenheim analyst Debjit Chattopadhyay initiated coverage of Prime Medicine with a Buy rating and $24 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PRME:
Questions or Comments about the article? Write to editor@tipranks.com